Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Huot

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Journal of Neural Transmission (Vienna, Austria : 1996)|April 5, 2020
Combined mGlu<sub>2</sub> orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmosetStephen G Nuara, Adjia Hamadjida, Cynthia Kwan, et al.
The European Journal of Neuroscience|July 29, 2023
The 5-HT<sub>2A/2C</sub> inverse agonist nelotanserin alleviates L-DOPA-induced dyskinesia in the MPTP-lesioned marmosetCynthia Kwan, Imane Frouni, Dominique Bédard, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 9, 2018
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmosetAdjia Hamadjida, Stephen G Nuara, Dominique Bédard, et al.
Neurobiology of Aging|November 6, 2010
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Plos One|March 17, 2011
Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synucleinJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Neuropharmacology|July 4, 2018
The highly selective 5-HT<sub>2A</sub> antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmosetAdjia Hamadjida, Stephen G Nuara, Dominique Bédard, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 5, 2020
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmosetAdjia Hamadjida, Stephen G Nuara, Cynthia Kwan, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 1, 2020
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmosetAdjia Hamadjida, Stephen G Nuara, Imane Frouni, et al.
Experimental Brain Research|November 17, 2018
5-HT<sub>2A</sub> blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-reviewCynthia Kwan, Imane Frouni, Dominique Bédard, et al.
Neuropharmacology|November 5, 2020
Selective blockade of the 5-HT<sub>3</sub> receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmosetCynthia Kwan, Stephen G Nuara, Dominique Bédard, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Journal of Neural Transmission (Vienna, Austria : 1996)|April 5, 2020
Combined mGlu<sub>2</sub> orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmosetStephen G Nuara, Adjia Hamadjida, Cynthia Kwan, et al.
The European Journal of Neuroscience|July 29, 2023
The 5-HT<sub>2A/2C</sub> inverse agonist nelotanserin alleviates L-DOPA-induced dyskinesia in the MPTP-lesioned marmosetCynthia Kwan, Imane Frouni, Dominique Bédard, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 9, 2018
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmosetAdjia Hamadjida, Stephen G Nuara, Dominique Bédard, et al.
Neurobiology of Aging|November 6, 2010
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Plos One|March 17, 2011
Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synucleinJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Neuropharmacology|July 4, 2018
The highly selective 5-HT<sub>2A</sub> antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmosetAdjia Hamadjida, Stephen G Nuara, Dominique Bédard, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 5, 2020
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmosetAdjia Hamadjida, Stephen G Nuara, Cynthia Kwan, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 1, 2020
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmosetAdjia Hamadjida, Stephen G Nuara, Imane Frouni, et al.
Experimental Brain Research|November 17, 2018
5-HT<sub>2A</sub> blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-reviewCynthia Kwan, Imane Frouni, Dominique Bédard, et al.
Neuropharmacology|November 5, 2020
Selective blockade of the 5-HT<sub>3</sub> receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmosetCynthia Kwan, Stephen G Nuara, Dominique Bédard, et al.
Pageof 11